Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors
Pharmaceutics · 15.02.2025 · 17 (2) · 260
DOI: 10.3390/pharmaceutics17020260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.02.2025. Verfasst von Alexandru Șandor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 C…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, Installations and Special Objectives of National Interest (IOSIN), MCID through the "Nucleu" Programme within the National Plan for Research, Development and In-novation 2022-2027.
Abstract (Originalsprache)
Background/Objectives: Angiogenesis plays a crucial role in tumor development and is a driving force for the aggressiveness of several types of cancer. Our team developed a novel series of thiosemicarbazone-containing quinazoline derivatives, TSC1-TSC10, as potential VEGFR2 inhibitors with proven anti-angiogenic and antiproliferative potential.
Methods
The TSC1-TSC10 series was synthesized and characterized by spectral data. Extensive methodology was applied both in vitro (Alamar Blue assay, Scratch assay, CAM assay, and VEGFR2 kinase assay) and in silico (docking studies, MDs, and MM-PBSA) for the confirmation of the biological potential.
Results
TSC10 emerged as the most promising compound, with a favorable cytotoxic potential across the cell panel (Ea.Hy296, HaCaT, and A375) in agreement with the in vitro VEGFR2 kinase assay (IC50 = 119 nM). A comparable motility reduction in the vascular endothelial cells to that of the reference drug sorafenib was provided by TSC10, with a similar anti-angiogenic potential in the more complex in ovo model of the CAM assay. The in silico experiments confirmed the successful accommodation of the active site of the kinase domain similar to sorafenib for the entire TSC1-TSC10 series, providing valuable key insight into the complex stability driving force for the evaluated compounds.
Conclusions
The in vitro evaluations of the biological potential correlated with the in silico predictions by computer-aided complex simulations provided a solid confirmation of the initial hypothesis for the TSC1-TSC10 series.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
- Department of Organic Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeş, 400012 Cluj-Napoca, Romania.
- Department of Toxicology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
- Department of Pharmacognosy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 12 Ion Creangă Street, 400010 Cluj-Napoca, Romania.
- National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donath Street, 400293 Cluj-Napoca, Romania.
- Department of Pharmaceutical Technology and Biopharmaceutics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babes, Street, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Alexandru Șandor, Gabriel Marc, Anca Stana, Ilioara Oniga, Adrian Pîrnău, Laurian Vlase, Ionuț-Valentin Creștin, Alex-Robert Jîjie, Brîndușa Tiperciuc
Förderung
- "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
- Installations and Special Objectives of National Interest (IOSIN)
- MCID through the "Nucleu" Programme within the National Plan for Research, Development and In-novation 2022-2027
- University of Medicine and Pharmacy, Cluj-Napoca, Romania
- Installations and Special Objectives of National Interest (IOSIN), IZOSTAB
- MCID through the “Nucleu” Programme within the National Plan for Research, Development and Innovation 2022–2027
Zitieren
APA
Șandor, A., Crișan, O., Marc, G., Fizeșan, I., Ionuț, I., Moldovan, C., Stana, A., Oniga, I., Pîrnău, A., Vlase, L., Petru, A. E., Creștin, I. V., Jîjie, A. R., Tiperciuc, B., & Oniga, O. (2025). Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors. Pharmaceutics, 17(2), 260. https://doi.org/10.3390/pharmaceutics17020260
Vancouver
Șandor A, Crișan O, Marc G, Fizeșan I, Ionuț I, Moldovan C, et al. Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors. Pharmaceutics. 2025;17(2):260. doi:10.3390/pharmaceutics17020260
BibTeX
@article{andor2025,
author = {Șandor, Alexandru and Crișan, Ovidiu and Marc, Gabriel and Fizeșan, Ionel and Ionuț, Ioana and Moldovan, Cristina and Stana, Anca and Oniga, Ilioara and Pîrnău, Adrian and Vlase, Laurian and Petru, Andreea-Elena and Creștin, Ionuț-Valentin and Jîjie, Alex-Robert and Tiperciuc, Brîndușa and Oniga, Ovidiu},
title = {Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {260},
doi = {10.3390/pharmaceutics17020260}
}
EUVIMED